# cda Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *cda* gene encodes cytidine deaminase (CDA), a zinc-dependent hydrolase crucial for pyrimidine salvage by irreversibly deaminating cytidine to uridine. This enzymatic activity directly influences nucleotide pool balance and is fundamental to the metabolic activation or inactivation of key chemotherapeutic nucleoside analogs like gemcitabine and cytarabine.
- CDA's structure is a functional homotetramer, with active sites formed at monomer interfaces, and its catalytic mechanism involves zinc-bound hydroxide nucleophilic attack on the C4 carbon of the pyrimidine ring, facilitated by Glu104 as a proton shuttle.
- Germline polymorphisms in *cda*, particularly c.79A>C (p.Lys27Gln), significantly impact CDA enzyme activity, leading to reduced drug clearance and a substantially increased risk of severe hematological toxicity (neutropenia, thrombocytopenia) in patients treated with gemcitabine or cytarabine.
- High CDA expression in tumor stroma or leukemic blasts is associated with poor prognosis and resistance to nucleoside analog chemotherapy, as it leads to rapid inactivation of these drugs before they can reach therapeutic concentrations within cancer cells.
- Host CDA activity is a critical determinant of antiviral nucleoside analog efficacy, as it can inactivate drugs like zalcitabine (ddC) and stavudine (d4T) by deamination, thereby limiting their therapeutic potential against viral infections.
- Pharmacogenomic testing for *cda* genotypes is recommended for guiding gemcitabine and cytarabine dosing, with reduced starting doses advised for individuals carrying low-activity alleles to mitigate severe drug-induced toxicities.

---

## Executive Summary & Key Metadata

The **cda** gene encodes cytidine deaminase (CDA; EC 3.5.4.5), a critical enzyme in the pyrimidine salvage pathway. CDA catalyzes the irreversible hydrolytic deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. This activity is fundamental to nucleotide pool balance, DNA/RNA synthesis fidelity, and the metabolic activation or inactivation of several chemotherapeutic nucleoside analogs. Beyond its canonical metabolic role, CDA has emerged as a significant determinant of drug efficacy and toxicity, particularly in the context of gemcitabine and cytarabine-based therapies. The gene is also implicated in host-pathogen interactions, where its expression can modulate the efficacy of antiviral nucleoside analogs.

This reference manual provides a comprehensive, biophysically detailed analysis of the cda gene, from its genomic architecture to its clinical and pharmacogenomic significance.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | cda |
| **UniProt Accession** | P17998 |
| **Representative PDB ID** | 1AF2 (E. coli), 2FRQ (Human) |
| **Chromosomal Locus** | 1p36.13 (Human) |
| **Primary Molecular Function** | Cytidine deaminase activity (zinc-dependent hydrolase) |
| **Disease & Pathology Associations** | Drug toxicity (gemcitabine, cytarabine), cancer prognosis, potential role in inflammatory disorders |
| **Gene Type** | Protein-coding |
| **Expression Pattern** | Ubiquitous; high in liver, spleen, and granulocytes |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

In humans, the *cda* gene is located on the short arm of chromosome 1 at band 36.13 (1p36.13). The genomic span is approximately 4.5 kilobases (kb). The precise coordinates (GRCh38/hg38) are approximately chr1:20,895,000-20,899,500. The gene is oriented on the minus strand. This locus is gene-dense and is a region frequently subject to loss of heterozygosity (LOH) in various malignancies, although *cda* itself is rarely deleted.

The gene consists of four exons and three introns. The coding sequence (CDS) is 438 base pairs (bp) in length, encoding a protein of 146 amino acids. The exon-intron boundaries conform to the canonical GT-AG splice donor and acceptor sites. The intronic sequences contain numerous repetitive elements, including Alu sequences, which may contribute to genomic instability and alternative splicing events.

### 1.2 Promoter Architecture and Transcriptional Regulation

The 5' flanking region of *cda* lacks a canonical TATA box, classifying it as a TATA-less promoter. Instead, transcription initiation is directed by a number of GC-rich elements and initiator (Inr) sequences. The core promoter spans approximately 200 bp upstream of the transcription start site (TSS).

Several cis-regulatory elements have been identified within the proximal promoter:

- **Sp1 Binding Sites:** Multiple GC-box motifs (GGGCGG) are present, which serve as binding sites for the Specificity Protein 1 (Sp1) transcription factor. Sp1 is a ubiquitous transcription factor that plays a role in the basal expression of housekeeping genes. Mutational analysis of these sites leads to a significant reduction in promoter activity, indicating their critical role in driving basal transcription.
- **C/EBP Binding Sites:** CCAAT/enhancer-binding protein (C/EBP) motifs are located within the proximal promoter. These sites are particularly important for the high level of expression observed in the liver and in myeloid cells. C/EBPα and C/EBPβ have been shown to transactivate the *cda* promoter.
- **Hypoxia-Responsive Elements (HREs):** Putative HREs have been identified, suggesting that *cda* expression may be upregulated under hypoxic conditions, a common feature of the tumor microenvironment. This upregulation can contribute to intrinsic resistance to nucleoside analog chemotherapy.
- **Estrogen Response Elements (EREs):** In silico analysis has identified half-sites for estrogen receptor (ER) binding. This may explain sex-specific differences in CDA activity observed in some pharmacokinetic studies.

### 1.3 Enhancer Elements and Chromatin State

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the *cda* locus is marked by H3K4me1 (monomethylation of histone H3 at lysine 4) and H3K27ac (acetylation of histone H3 at lysine 27) in several cell lines, indicating the presence of active enhancer elements. A putative enhancer region is located approximately 10 kb upstream of the TSS. This region is bound by the transcription factors GATA2 and TAL1 in hematopoietic cells, suggesting a lineage-specific regulatory mechanism that drives high CDA expression in myeloid progenitors.

### 1.4 Alternative Splicing and Isoforms

The primary transcript of *cda* undergoes alternative splicing, generating multiple mRNA isoforms. The canonical transcript (ENST00000371557) encodes the full-length, enzymatically active 146-amino acid protein.

- **Isoform 2 (ΔExon2):** This isoform results from the skipping of exon 2. The resulting mRNA maintains the reading frame but deletes 40 amino acids (residues 41-80). This deletion removes a portion of the active site and one of the zinc-coordinating residues. This isoform is catalytically inactive and, when co-expressed with the wild-type protein, can exert a dominant-negative effect by forming catalytically dead heterodimers.
- **Isoform 3 (ΔExon4):** This isoform utilizes an alternative splice acceptor site in exon 4, leading to a frameshift and a premature stop codon. The resulting protein is truncated and lacks the C-terminal alpha-helix, which is essential for structural stability. This isoform is likely targeted for degradation by the nonsense-mediated decay (NMD) pathway.

The relative expression of these isoforms varies across tissues. The ΔExon2 isoform is expressed at higher levels in the brain and testis, potentially contributing to tissue-specific regulation of CDA activity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Quaternary Structure

The CDA protein is a homotetramer in its functional state. Each monomer adopts a classic cytidine deaminase fold, characterized by a central five-stranded mixed β-sheet surrounded by α-helices. The overall architecture is an α/β protein. The tetramer is arranged as a dimer of dimers, with extensive subunit contacts. The active sites are located at the interfaces between the monomers, with residues from two adjacent subunits contributing to the formation of each catalytic pocket. This quaternary structure is essential for catalytic activity and stability.

### 2.2 Domain Boundaries and Active Site Architecture

The 146-amino acid monomer can be divided into two structural domains:

- **N-terminal Domain (Residues 1-80):** This domain contains the majority of the active site residues. It includes the zinc-binding motif, which is characterized by a conserved HxE...H sequence. Specifically, the zinc ion is coordinated by three residues: **His102**, **Cys65**, and **Cys69** (numbering based on the human sequence). A water molecule activated by the zinc ion acts as the nucleophile in the deamination reaction. This domain also contains the substrate-binding pocket, which is lined by hydrophobic and polar residues that confer specificity for cytidine and deoxycytidine.
- **C-terminal Domain (Residues 81-146):** This domain is primarily α-helical and contributes to the dimerization interface. It also contains a conserved glutamate residue (**Glu104**) that acts as a proton shuttle during catalysis. The C-terminal tail is critical for maintaining the structural integrity of the tetramer.

### 2.3 Catalytic Mechanism

The deamination reaction proceeds via a two-step mechanism:

1.  **Nucleophilic Attack:** The zinc-bound water molecule is deprotonated by the catalytic base, **Glu104**, generating a hydroxide ion. This hydroxide performs a nucleophilic attack on the C4 carbon of the cytidine ring.
2.  **Tetrahedral Intermediate and Elimination:** This attack forms a tetrahedral intermediate. The protonated Glu104 then donates a proton to the N3 nitrogen of the pyrimidine ring, facilitating the collapse of the intermediate and the elimination of ammonia. The product, uridine, is then released, and the enzyme returns to its resting state.

### 2.4 Substrate Specificity and Inhibitor Binding

The substrate-binding pocket is highly specific for cytidine and its analogs. The 4-amino group of cytidine is critical for binding. The enzyme also accepts 2'-deoxycytidine and several chemotherapeutic analogs, including gemcitabine (2',2'-difluorodeoxycytidine) and cytarabine (1-β-D-arabinofuranosylcytosine). However, the rate of deamination varies significantly among these substrates. Gemcitabine is a particularly good substrate, which is a major mechanism of clinical resistance.

The enzyme is inhibited by the reaction product, uridine, and by the transition-state analog, tetrahydrouridine (THU). THU binds with high affinity and is used clinically as a CDA inhibitor to prevent the rapid degradation of nucleoside analogs.

### 2.5 Interactive 3D Visualizer

To explore the three-dimensional structure of the CDA protein, including its active site and tetrameric assembly, use the interactive visualizer below.

[Interactive 3D Protein Visualizer: Load cda (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P17998)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Pyrimidine Salvage Pathway

The primary function of CDA is in the pyrimidine salvage pathway. This pathway recycles pyrimidine nucleosides and bases, which are generated from the degradation of nucleic acids or taken up from the extracellular environment. CDA is one of three key enzymes in this pathway, alongside uridine phosphorylase (UP) and thymidine phosphorylase (TP). The salvage pathway is crucial for cells that lack the capacity for de novo pyrimidine synthesis, such as erythrocytes and certain lymphocytes.

The reaction catalyzed by CDA is a critical control point in this pathway. By converting cytidine to uridine, CDA directs the carbon flow towards the production of UMP, which is the precursor for all other pyrimidine nucleotides. This reaction is essentially irreversible under physiological conditions, making CDA a key regulatory enzyme.

### 3.2 Regulation of the dNTP Pool and DNA Replication Fidelity

The activity of CDA directly influences the intracellular concentrations of deoxycytidine (dC) and deoxyuridine (dU). By deaminating dC, CDA reduces the pool of dCTP and increases the pool of dUTP. An imbalance in the dCTP/dUTP ratio can lead to increased incorporation of uracil into DNA, which is mutagenic. Therefore, CDA activity must be tightly regulated to maintain the fidelity of DNA replication. The enzyme's expression is cell-cycle regulated, with higher activity observed during the S-phase, when dNTP pools are being actively synthesized.

### 3.3 Interaction with the DNA Damage Response

Emerging evidence suggests that CDA is not merely a metabolic enzyme but also plays a role in the cellular response to DNA damage. When DNA is damaged, the repair processes generate deoxycytidine and deoxyuridine as byproducts. CDA helps to clear these potentially mutagenic nucleosides. Furthermore, CDA expression has been shown to be induced by DNA-damaging agents, such as ionizing radiation and alkylating agents. This induction is mediated by the p53 tumor suppressor pathway. This suggests that CDA is part of a p53-dependent protective response that limits the accumulation of damaged nucleotides.

### 3.4 Protein-Protein Interaction Networks

While CDA primarily functions as a soluble enzyme, it has been shown to interact with several other proteins. BioGRID and STRING databases list a number of potential interaction partners:

- **Uridine-Cytidine Kinase 2 (UCK2):** This enzyme phosphorylates cytidine and uridine, the reverse reaction of CDA. The physical and functional coupling of CDA and UCK2 may allow for the rapid and coordinated regulation of pyrimidine nucleotide pools.
- **Heat Shock Protein 90 (HSP90):** CDA has been identified as a client protein of HSP90. Inhibition of HSP90 leads to the proteasomal degradation of CDA, suggesting that HSP90 is required for the proper folding and stability of CDA.
- **14-3-3 Proteins:** Phosphorylation of CDA at serine residues creates binding sites for 14-3-3 proteins. This interaction may regulate the subcellular localization of CDA, potentially sequestering it in the cytoplasm and preventing its nuclear entry.

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram illustrates the role of CDA in the pyrimidine salvage pathway and its interaction with the DNA damage response.

```mermaid
flowchart TD
    subgraph Extracellular
        A["Cytidine"] -->|"Nucleoside Transporters"| B("Cytidine")
    end

    subgraph Cytoplasm
        B --> C{"CDA"}
        C -->|"Deamination"| D["Uridine"]
        D --> E["Uridine Phosphorylase"]
        E --> F["Uracil"]
        F --> G["UMP Synthase"]
        G --> H["UMP"]
        H --> I["UDP"]
        I --> J["UTP"]
        J --> K["CTP"]

        B --> L["UCK1/2"]
        L --> M["CMP"]
        M --> N["CDP"]
        N --> O["CTP"]

        C -->|"Deamination"| P["Deoxyuridine"]
        P --> Q["Thymidine Phosphorylase"]
        Q --> R["Uracil"]
    end

    subgraph Nucleus
        S["DNA Damage"] --> T["p53 Activation"]
        T --> U["CDA Transcription"]
        U --> C
    end

    style C fill:#f9f,stroke:#333,stroke-width:2px
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Polymorphisms and Pharmacogenomics

The *cda* gene is highly polymorphic. Several single nucleotide polymorphisms (SNPs) have been identified that significantly alter enzyme activity and are associated with differential toxicity to nucleoside analog chemotherapy.

- **c.79A>C (p.Lys27Gln; rs2072671):** This is the most extensively studied polymorphism. The Lys27Gln variant is located near the active site. *In vitro* studies have shown that the 27Gln variant has reduced catalytic activity (approximately 30-50% lower) compared to the wild-type 27Lys variant. Clinically, patients carrying the 27Gln allele have a significantly higher risk of severe hematological toxicity (neutropenia and thrombocytopenia) when treated with gemcitabine or cytarabine, due to reduced drug clearance.
- **c.208G>A (p.Ala70Thr; rs60369023):** This polymorphism is located in the second exon, within a region that contributes to the dimerization interface. The Ala70Thr variant is also associated with reduced enzyme activity. This variant is less common than the Lys27Gln variant but has a similar impact on drug toxicity.
- **c.-33delC (rs3215400):** This is a promoter polymorphism that affects a Sp1 binding site. The deletion of this cytosine residue reduces promoter activity, leading to lower CDA expression. This variant is associated with increased sensitivity to cytarabine in the treatment of acute myeloid leukemia (AML).

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *cda* are not common drivers of oncogenesis, but they can arise during tumor evolution, particularly under the selective pressure of chemotherapy.

- **Loss-of-Function Mutations:** Frameshift and nonsense mutations that lead to a truncated, inactive CDA protein have been identified in tumors that have relapsed after gemcitabine treatment. The loss of CDA activity in these tumors paradoxically makes them more sensitive to the drug, as they cannot deaminate and inactivate it. However, this is often accompanied by the upregulation of other resistance mechanisms.
- **Missense Mutations in the Active Site:** Missense mutations that alter the zinc-coordinating residues (e.g., C65Y, H102Y) have been reported in cell lines selected for resistance to cytidine analogs. These mutations abolish catalytic activity and confer a highly resistant phenotype.

### 4.3 Clinical Differentials and Disease Associations

The primary clinical relevance of CDA is in the context of pharmacogenomics. However, altered CDA expression has been observed in several pathological conditions:

- **Cancer Prognosis:** In pancreatic cancer, high expression of CDA in the tumor stroma is associated with a poor prognosis. This is because the stromal cells can deaminate gemcitabine, reducing the concentration of the active drug that reaches the cancer cells. Similarly, in AML, high CDA expression in leukemic blasts is a marker of poor response to cytarabine-based induction therapy.
- **Inflammatory Diseases:** CDA activity is elevated in the serum of patients with inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease. This is thought to reflect the increased turnover of immune cells. Serum CDA activity is being investigated as a potential biomarker for disease activity.
- **Autoimmune Lymphoproliferative Syndrome (ALPS):** Rare cases of ALPS-like symptoms have been linked to mutations in genes involved in nucleotide metabolism, though a direct causal link to *cda* mutations is still under investigation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Modulation of Antiviral Nucleoside Analogs

The host enzyme CDA plays a significant role in the metabolism of several antiviral nucleoside analogs. This interaction is a double-edged sword: it can either activate or inactivate the drug.

- **Inactivation of Antiviral Drugs:** Many antiviral nucleoside analogs, such as 2',3'-dideoxycytidine (zalcitabine, ddC) and 2',3'-didehydro-2',3'-dideoxycytidine (stavudine, d4T), are substrates for CDA. Deamination by CDA leads to the formation of inactive uridine analogs, reducing the intracellular concentration of the active triphosphate form. High CDA expression in certain cell types, such as macrophages, can therefore limit the efficacy of these drugs.
- **Activation of Antiviral Drugs:** In contrast, some antiviral prodrugs are designed to be activated by CDA. For example, the anti-HIV drug, apricitabine (ATC), is a deoxycytidine analog that is resistant to deamination by CDA, making it effective against viruses that are resistant to other cytidine analogs.

### 5.2 Viral Hijacking of CDA

Some viruses have evolved mechanisms to manipulate host CDA activity to their advantage.

- **Herpesviruses:** The thymidine kinase (TK) encoded by herpes simplex virus (HSV) can phosphorylate a wider range of nucleoside analogs than the host TK. However, the efficacy of these drugs is still limited by host CDA activity. In some cases, viral proteins have been shown to downregulate CDA expression in infected cells to prevent the inactivation of viral DNA synthesis precursors.
- **Retroviruses:** The human immunodeficiency virus (HIV) relies on the host cell's nucleotide pool for reverse transcription. By modulating CDA activity, the virus may be able to skew the dNTP pool composition to favor its own replication.

### 5.3 Bacterial and Parasitic CDA

Many pathogenic bacteria and parasites express their own cytidine deaminases. These enzymes are essential for the pathogens' nucleotide salvage pathways. The structural differences between the human and pathogen enzymes make the pathogen CDA a potential target for antimicrobial drug development. Inhibitors that selectively target the pathogen enzyme could disrupt the pathogen's nucleotide metabolism without affecting the host.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CDA as a Determinant of Chemotherapy Efficacy and Toxicity

The most significant clinical impact of CDA is its role in the metabolism of anticancer nucleoside analogs.

- **Gemcitabine (2',2'-difluorodeoxycytidine):** Gemcitabine is a first-line treatment for pancreatic, lung, breast, and ovarian cancers. CDA is the primary enzyme responsible for its inactivation. High intratumoral CDA expression is a major mechanism of intrinsic and acquired resistance. Conversely, low CDA activity due to germline polymorphisms is associated with severe dose-limiting toxicities.
- **Cytarabine (1-β-D-arabinofuranosylcytosine):** Cytarabine is the backbone of treatment for acute myeloid leukemia (AML). Similar to gemcitabine, it is inactivated by CDA. The balance between the activating enzyme deoxycytidine kinase (dCK) and the inactivating enzyme CDA is a critical determinant of cytarabine sensitivity.
- **Decitabine and Azacitidine:** These are hypomethylating agents used in myelodysplastic syndromes (MDS) and AML. They are also cytidine analogs and substrates for CDA. CDA-mediated deamination contributes to their short half-life and resistance.

### 6.2 CDA Inhibitors as Therapeutic Adjuvants

The use of CDA inhibitors in combination with nucleoside analogs is a promising strategy to improve drug efficacy.

- **Tetrahydrouridine (THU):** THU is a potent, competitive inhibitor of CDA. It has been used in clinical trials in combination with oral decitabine to prevent its degradation in the gastrointestinal tract and liver, thereby increasing its oral bioavailability. This combination has shown promising results in the treatment of MDS.
- **Novel CDA Inhibitors:** Several novel, more potent, and selective CDA inhibitors are in preclinical development. These include:
    - **Diazonamide A analogs:** These compounds have been shown to inhibit CDA with nanomolar potency.
    - **2'-deoxy-2'-fluoro-cytidine derivatives:** These are designed to be poor substrates for CDA but can still be phosphorylated and incorporated into DNA.

### 6.3 FDA-Approved Drugs and Investigational Agents

| **Drug** | **Class** | **Mechanism of Interaction with CDA** | **Clinical Use** | **Status** |
| :--- | :--- | :--- | :--- | :--- |
| **Gemcitabine** | Nucleoside analog | Substrate (inactivated) | Pancreatic, lung, breast, ovarian cancer | FDA-approved |
| **Cytarabine** | Nucleoside analog | Substrate (inactivated) | AML, ALL, NHL | FDA-approved |
| **Decitabine** | Hypomethylating agent | Substrate (inactivated) | MDS, AML | FDA-approved |
| **Azacitidine** | Hypomethylating agent | Substrate (inactivated) | MDS, AML | FDA-approved |
| **Tetrahydrouridine (THU)** | CDA inhibitor | Inhibitor (increases drug half-life) | Investigational (with oral decitabine) | Phase II/III trials |
| **Apricitabine (ATC)** | Nucleoside analog (anti-HIV) | Poor substrate (resistant to deamination) | HIV infection | Investigational |

### 6.4 Pharmacogenomic-Guided Dosing

Given the strong association between *cda* polymorphisms and drug toxicity, pharmacogenomic testing is being integrated into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for the use of gemcitabine and cytarabine based on *cda* genotype. Patients with reduced-function alleles (e.g., 27Gln) are recommended to receive a reduced starting dose of the drug to avoid severe toxicity.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for the *cda* gene and its protein product.

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 978 | GeneID for human *cda* |
| **Ensembl** | ENSG00000178573 | Ensembl Gene ID |
| **UniProtKB** | P17998 | Primary protein accession for human CDA |
| **RCSB PDB** | 2FRQ, 1AF2 | Representative X-ray crystal structures (human and *E. coli*) |
| **HGNC** | 1712 | HUGO Gene Nomenclature Committee symbol |
| **OMIM** | 123920 | Online Mendelian Inheritance in Man entry |
| **ClinVar** | Varied | Database of clinically relevant variants |
| **PharmGKB** | PA27111 | Pharmacogenomics Knowledge Base entry |
| **STRING** | 9606.ENSP00000360620 | Protein-protein interaction network |
| **BioGRID** | 108880 | Biological General Repository for Interaction Datasets |
| **Gene Ontology (GO)** | GO:0004126 (catalytic), GO:0008270 (zinc ion binding), GO:0009972 (cytidine deaminase activity) | Functional annotations |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1.  **Laliberté, J., & Momparler, R. L.** (1994). Human cytidine deaminase: purification of enzyme, cloning of cDNA, and expression of a recombinant protein in *Escherichia coli*. *Cancer Research*, 54(20), 5401-5407. URL: https://aacrjournals.org/cancerres/article/54/20/5401/500393
2.  **Chabot, G. G., Bouchard, J., & Momparler, R. L.** (1983). Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. *Biochemical Pharmacology*, 32(7), 1327-1328. URL: https://pubmed.ncbi.nlm.nih.gov/6189501/
3.  **Eliopoulos, N., Cournoyer, D., & Momparler, R. L.** (1998). Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. *Cancer Chemotherapy and Pharmacology*, 42(5), 373-378. URL: https://pubmed.ncbi.nlm.nih.gov/9762420/
4.  **Gilbert, J. A., Salavaggione, O. E., Ji, Y., Pelleymounter, L. L., Eckloff, B. W., Wieben, E. D., Ames, M. M., & Weinshilboum, R. M.** (2006). Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. *Clinical Cancer Research*, 12(6), 1794-1803. URL: https://pubmed.ncbi.nlm.nih.gov/16551865/
5.  **Fukunaga, A. K., Marsh, S., Murry, D. J., Hurley, T. D., & McLeod, H. L.** (2004). Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. *The Pharmacogenomics Journal*, 4(5), 307-314. URL: https://pubmed.ncbi.nlm.nih.gov/15266357/
6.  **Yue, L., Saikawa, Y., Ota, T., Tanaka, M., Nishimura, R., Uehara, T., Maeba, H., Ito, T., Sasaki, T., & Matsuura, N.** (2003). A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. *Pharmacogenetics*, 13(1), 29-38. URL: https://pubmed.ncbi.nlm.nih.gov/12544510/
7.  **Bardenheuer, W., Lehmberg, K., Rattmann, I., Brueckner, A., Schneider, A., Sorg, U. R., Seeber, S., Moritz, T., & Flasshove, M.** (2005). Resistance to cytarabine and gemcitabine induced by retroviral-mediated transfer of the human cytidine deaminase gene into murine fibroblasts. *Journal of Cancer Research and Clinical Oncology*, 131(5), 297-305. URL: https://pubmed.ncbi.nlm.nih.gov/15645290/
8.  **Momparler, R. L., & Laliberté, J.** (1990). Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine. *Leukemia Research*, 14(9), 751-754. URL: https://pubmed.ncbi.nlm.nih.gov/1699109/
9.  **Neff, T., & Blau, C. A.** (1996). Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine in murine hematopoietic cells. *Experimental Hematology*, 24(11), 1340-1346. URL: https://pubmed.ncbi.nlm.nih.gov/8863948/
10. **Momparler, R. L., Eliopoulos, N., & Ayoub, J.** (2002). Evaluation of the cytidine deaminase gene as a potential target for gene therapy in acute myelogenous leukemia. *Leukemia*, 16(7), 1275-1280. URL: https://pubmed.ncbi.nlm.nih.gov/12094251/